⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1403442 | 0.67 | — | — | |
| SCHEMBL2407064 | 0.65 | — | — | |
| SCHEMBL11331916 | 0.60 | — | — | |
| SCHEMBL11152394 | 0.60 | — | — | |
| SCHEMBL22296900 | 0.60 | — | — | |
| SCHEMBL6701485 | 0.58 | — | — | |
| SCHEMBL129646 | 0.47 | — | — | |
| SCHEMBL10545264 | 0.47 | — | — | |
| SCHEMBL6765508 | 0.47 | — | — | |
| SCHEMBL239887 | 0.47 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 840 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4389745-A1 | PYRIDONE COMPOUND HAVING INTEGRASE INHIBITORY ACTIVITY AND PHARMACEUTICAL USE THEREOF | Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) | 2024-06-26 | — | — | EP | claimed |
| CN-118201930-A | WEE1 protein kinase degradation agent and application thereof | 杭州格博生物医药有限公司 | 2024-06-14 | — | — | CN | claimed |
| EP-4375277-A1 | LPA1 SMALL MOLECULE ANTAGONIST | Tuojie Biotech (Shanghai) Co., Ltd. (CN) | 2024-05-29 | — | — | EP | claimed |
| WO-2024088296-A1 | PIPERIDINOPYRIMIDINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF IN MEDICINE | 上海拓界生物医药科技有限公司 | 2024-05-02 | — | — | WO | claimed |
| CN-117886814-A | PD-1/PD-L1 small molecule inhibitor and application thereof in medicines | 广东东阳光药业股份有限公司 | 2024-04-16 | — | — | CN | claimed |
| CN-117715908-A | Pyridone compounds having integrase inhibitory activity and their pharmaceutical use | 江苏恒瑞医药股份有限公司 | 2024-03-15 | — | — | CN | claimed |
| WO-2024027814-A1 | COMPOUND HAVING KRAS G12D INHIBITORY EFFECT | 杭州中美华东制药有限公司 | 2024-02-08 | — | — | WO | claimed |
| CN-117460721-A | LPA1 small molecule antagonist | 上海拓界生物医药科技有限公司 | 2024-01-26 | — | — | CN | claimed |
| WO-2023141593-A2 | PROCESS FOR SYNTHESIS OF GALBULIMIMA ALKALOID 18 AND COMPOUNDS USEFUL AS OPIOID RECEPTOR ANTAGONISTS AND AGONISTS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2023-07-27 | — | — | WO | claimed |
| WO-2023115167-A1 | COMPOUNDS | Psylo Pty Ltd (AU) | 2023-06-29 | — | — | WO | claimed |
| WO-1997042174-A1 | SUBSTITUTED INDAZOLE DERIVATIVES AND THEIR USE AS INHIBITORS PHOSPHODIESTERASE (PDE) TYPE IV AND THE PRODUCTION OF TUMOR NECROSIS FACTOR (TNF) | PFIZER INC. (US) | 1997-11-13 | — | — | WO | claimed |
| US-5596013-A | INHIBITORS OF PHOSPHODIESTERASE TYPE IV AND PRODUCTION OF TUMOR NECROSIS FACTOR | PFIZER INC (US) | 1997-01-21 | — | — | US | claimed |
| EP-0738270-A1 | DIHYDRO PYRAZOLOPYRROLES | PFIZER INC. (US) | 1996-10-23 | — | — | EP | claimed |
| US-5543406-A | TREATING ANDROGEN RESPONSIVE OR MEDIATED DISEASE | GLAXO WELLCOME, INC. (US) | 1996-08-06 | — | — | US | claimed |
| US-5508300-A | INHIBIT PHOSPHODIESTERASE AND PRODUCTION OF TUMOR NECROSIS FACTOR; TREATING INFLAMMATORY DISEASES | PFIZER INC. (US) | 1996-04-16 | — | — | US | claimed |
| EP-0674651-A1 | SUBSTITUTED 6-AZAANDROSTENONES | GLAXO WELLCOME INC. (US) | 1995-10-04 | — | — | EP | claimed |
| WO-1995019362-A1 | DIHYDRO PYRAZOLOPYRROLES | PFIZER INC. (US) | 1995-07-20 | — | — | WO | claimed |
| EP-0641356-A1 | INHIBITORS OF 5-ALPHA-TESTOSTERONE REDUCTASE | GLAXO WELLCOME INC. (US) | 1995-03-08 | — | — | EP | claimed |
| WO-1994014833-A2 | SUBSTITUTED 6-AZAANDROSTENONES | GLAXO WELLCOME INC. (US) | 1994-07-07 | — | — | WO | claimed |
| WO-1993013124-A1 | INHIBITORS OF 5-ALPHA-TESTOSTERONE REDUCTASE | GLAXO INC. (US) | 1993-07-08 | — | — | WO | claimed |